Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | D2C7-IT |
Synonyms | |
Therapy Description |
D2C7-IT is an immunotoxin engineered by linking a fragment of the D2C7 monoclonal antibody recognizing wild-type EGFR and EGFRvIII with Pseudomonas Exotoxin A (PE38KDEL), which targets tumor cells expressing wild-type EGFR and/or EGFRvIII, potentially resulting in decreased tumor growth (PMID: 28286803, PMID: 31142380). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
D2C7-IT | D2C7-(scdsFv)-PE38KDEL | D2C7-IT is an immunotoxin engineered by linking a fragment of the D2C7 monoclonal antibody recognizing wild-type EGFR and EGFRvIII with Pseudomonas Exotoxin A (PE38KDEL), which targets tumor cells expressing wild-type EGFR and/or EGFRvIII, potentially resulting in decreased tumor growth (PMID: 28286803, PMID: 31142380). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02303678 | Phase I | D2C7-IT | D2C7 for Adult Patients With Recurrent Malignant Glioma | Completed | USA | 0 |